Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Inactivated Polio Vaccine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Vaccination
1 trial -
Inactivated SARS-CoV-2 vaccine coadministered with vricella vaccine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
SARS-CoV-2 Infection
1 trial -
Individual ATG
The First People's Hospital of Lianyungang
Hematopoietic Stem Cell Transplantation
1 trial -
Infliximab
The First People's Hospital of Lianyungang
Crohn's Diseases
1 trial -
Insulin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pancreatitis, Acute
1 trial -
Insulin
The First People's Hospital of Lianyungang
Brain Injuries
1 trial -
Insulin
The First People's Hospital of Lianyungang
Acute Pancreatitis
1 trial -
Intensive statin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Coronary Artery Disease
1 trial -
Intranasal corticosteroids (INCS) combined with oral antihistamines (OAH) used for treatment
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Allergic Rhinitis
1 trial -
Intranasal dexmedetomidine-esketamine
The First People's Hospital of Lianyungang
Adenotonsillectomy
1 trial -
Intraosseous
Hospital Authority, Hong Kong
Cardiac Arrest
1 trial -
Intraosseous Morphine
Hospital Authority, Hong Kong
Pain Postoperative
1 trial -
Intravenous Immunoglobulins, Human
The First People's Hospital of Lianyungang
Guillain-Barre Syndrome
1 trial -
Intravenous thrombolysis + edaravone
The First People's Hospital of Lianyungang
Ischemic Stroke
1 trial -
Irinotecan liposomes combined with cisplatin/carboplatin
The First People's Hospital of Lianyungang
Neuroendocrine Tumors
1 trial -
Isatuximab, bortezomib, lenalidomide, dexamethason
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Multiple Myeloma
1 trial -
Isoniazid
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Tuberculosis, Pulmonary
1 trial -
Isoniazid Aminosalicylate Tablets
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Reinfection Pulmonary Tuberculosis
1 trial -
Ixazomib
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
Ixekizumab
Hospital Authority, Hong Kong
Plaque Psoriasis
1 trial -
JAK Inhibitor
The First People's Hospital of Lianyungang
Dermatomyositis, Adult Type
1 trial -
Jejunostomy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Cancer
1 trial -
KANG FU PEN
The First People's Hospital of Lianyungang
Cervical Cancer
1 trial -
Kanglaite Injection+Chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
NSCLC
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources